https://www.selleckchem.com/products/ml264.html
or dasotraline vs. placebo, consisted of decreased appetite (19.7% vs. 6.9%), decreased weight (12.1% vs. 0%), and increased weight (0.6% vs. 1.3%). CONCLUSION Among patients completing 12 weeks of treatment with dasotraline, weight reduction ≥5% was observed in 45% of obese patients with a BMI ≥30. The most frequent weight-related adverse event was decreased appetite, reported in approximately one in five patients treated with dasotraline.Clinicaltrials.gov number NCT02564588. FUNDING ACKNOWLEDGEMENTS Supported by funding from Sunovion P
Like
Comment
Share
